Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: A cross-sectional survey

Clinical Therapeutics

Volumn 25, Issue 6, 2003, Pages 1750-1764

  Gross, Cary P ^a,f   Vogel, Eric W ^b   Dhond, Abhay J ^a   Marple, Cheryl B ^c   Edwards, Roger A ^d,e   Hauch, Ole ^c   Demers, Elizabeth A ^b   Ezekowitz, Michael ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c ASTRAZENECA   (United Kingdom)

^d Health Services Consulting Corp   (United States)

^e TIAX LLC   (United States)

^f YALE UNIVERSITY   (United States)

Author keywords

Cerebrovascular accident; Hemorrhage; Nonvalvular atrial fibrillation; Perception; Warfarin

Indexed keywords

WARFARIN;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; AVERSION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DECISION MAKING; DISEASE ASSOCIATION; DRUG PREFERENCE; DRUG USE; EMPLOYMENT; FEMALE; GENDER; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOMES RESEARCH; PHYSICIAN ATTITUDE; REIMBURSEMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 0038693328     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80167-4     Document Type: Article

References (48)

1. Caro JJ, Groome PA, Flegel KM. Atrial fibrillation and anticoagulation: From randomised trials to practice. Lancet. 1993;154:1443-1448.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke. 1991;22:983-988.
3. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from 5 randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
4. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996;156:2537-2541.
5. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000;160:41-46.
6. Cohen N, Almoznino-Sarafian D, Alon I, et al. Warfarin for stroke prevention still underused in atrial fibrillation: Patterns of omission. Stroke. 2000;31:1217-1222.
7. Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of under-use of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31:822-827.
8. Adhiyaman V, Kamalakannan D, Oke A, et al. Underutilization of antithrombotic therapy in atrial fibrillation. J R Soc Med. 2000;93:138-140.
9. Flaker GC, McGowan DJ, Boechler M, et al. Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. Am Heart J. 1999;137:307-312.
10. Gajewski J, Singer RB. Mortality in an insured population with atrial fibrillation. JAMA. 1981;245:1540-1544.
11. Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA. 1999;281:1830-1835.
12. Mendelson G, Aronow WS. Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke. J Am Geriatr Soc. 1998;46:1423-1424.
13. Copland M, Walker ID, Tait RC. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med. 2001;161:2125-2128.
14. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: Observational study. BMJ. 2001;323:1218-1222.
15. Man-Son-Hing M, Laupacis A, O'Connor AM, et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: A randomized controlled trial. JAMA. 1999;282:737-743.
16. Fahey T, Montgomery AA, Peters TJ. Warfarin therapy for atrial fibrillation: The patient's preference is important. Arch Intern Ned. 2000;160:2403.
17. McCormick D, Gurwitz JH, Goldberg RJ, Ansell J. Long-term anticoagulation therapy for atrial fibrillation in elderly patients: Efficacy, risk, and current patterns of use. J Thromb Thrombolysis. 1999;7:157-163.
18. Monette J, Gurwitz JH, Rochon PA, Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: Results of a survey of long-term care practitioners. J Am Geriatr Soc. 1997;45:1060-1065.
19. Beyth RJ, Antani MR, Covinsky KE, et al. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med. 1996;11:721-728.
20. Chang HJ, Bell JR, Deroo DB, et al, for the Dartmouth Primary Care COOP Project. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med. 1990;150:81-84.
21. Lee TH, Pearson SD, Johnson PA, et al. Failure of information as an intervention to modify clinical management. A time-series trial in patients with acute chest pain. Ann Intern Med. 1995;122:434-437.
22. Gross CP, Canto MI, Hixson J, Powe NR. Management of Barrett's esophagus: A national study of practice patterns and their cost implications. Am J Gastroenterol. 1999;94:3440-3447.
23. Poses RM, Cebul RD, Wigton RS. You can lead a horse to water - improving physicians' knowledge of probabilities may not affect their decisions. Med Decis Making. 1995;15:65-75.
24. Rodgers H, Sudlow M, Dobson R, et al. Warfarin anticoagulation in primary care: A regional survey of present practice and clinicians' views. Br J Gen Pract. 1997;47:309-310.
25. Matchar DB, Samsa GP, Cohen SJ. Should we just let the anticoagulation service do it? The conundrum of anticoagulation for atrial fibrillation. J Gen Intern Med. 1996;11:768-770.
26. Baron J, Holzman GB, Schulkin J. Attitudes of obstetricians and gynecologists toward hormone replacement therapy. Med Decis Making. 1998;18:406-411.
27. Holtgrave DR, Lawler F, Spann SJ. Physicians' risk attitudes, laboratory usage, and referral decisions: The case of an academic family practice center. Med Decis Making. 1991;11:125-130.
28. Nightingale SD. Risk preference and laboratory test selection. J Gen Intern Med. 1987;2:25-28.
29. Allison JJ, Kiefe CI, Cook EF, et al. The association of physician attitudes about uncertainty and risk taking with resource use in a Medicare HMO. Med Decis Making. 1998;18:320-329.
30. Laupacis A, Singer D, Jacobsen A, et al. Risk factors for stroke and primary prevention of stroke in atrial fibrillation. J Thromb Thrombolysis. 1999;7:21-26.
31. Nightingale SD, Grant M. Risk preference and decision making in critical care situations. Chest. 1988;93:684-687.
32. McNemar Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika. 1947;12:153-157.
33. Sprent P. Applied Nonparametric Statistical Methods. 2nd ed. New York: Chapman and Hall; 1993.
34. Scheffé H. The Analysis of Variance. New York: John Wiley & Sons; 1959.
35. Stata Statistical Software. Release: 6.0 Reference Manual. Vol 4. College Station, Tex: Stata Press; 1999:8-14.
36. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA. 1993;269:2386-2391.
37. Feinstein AP. The 'chagrin factor' and qualitative decision analysis. Arch Intern Med. 1985;145:1257-1259.
38. Kosecoff J, Kanouse DE, Rogers WH, et al. Effects of the National Institutes of Health Consensus Development Program on physician practice. JAMA. 1987;258:2708-2713.
39. Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med. 2001;161:1443-1447.
40. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158:1641-1647.
41. Pubentz MJ, Calcagno DE Jr, Teeters JL. Improving warfarin anticoagulation therapy in a community health system. Pharm Pract Manag Q. 1998;18:1-16.
42. Garabedian-Ruffalo SM, Gray DR, Sax MJ, Ruffalo RL. Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. Am J Hosp Pharm. 1985;42:304-308.
43. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and pro-long life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
44. Hamby L, Weeks WB, Malinkowski C. Complications of warfarin therapy: Causes, costs, and the role of the anticoagulation clinic. Eff Clin Pract. 2000;3:179-184.
45. White RH, McCurdy SA, von Marensdorff H, et al. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study. Ann Intern Med. 1989;111:730-737.
46. Lafata JE, Martin SA, Kaatz S, Ward RE. Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: A cost-effectiveness analysis. J Thromb Thrombosis. 2000;9(Suppl 1):S13-S19.
47. Lafata JE, Martin SA, Kaatz S, Ward RE. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med. 2000;15:31-37.
48. Frykman V, Beerman B, Ryden L, Rosenqvist M. Management of atrial fibrillation: Discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J. 2001;22:1954-1959.